Ethnic differences in drug metabolism

被引:20
作者
Zhou, HH [1 ]
Liu, ZO [1 ]
机构
[1] Hunan Med Univ, Pharmacogenet Res Inst, Changsha 410078, Hunan, Peoples R China
关键词
ethnic differences; genetics polymorphism; CYP2D6; CYP2C19; drug metabolism; pharmacogenetics; gene dosage effect;
D O I
10.1515/CCLM.2000.131
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Ethnic differences in drug metabolism are well documented for a number of drugs. The molecular mechanisms responsible for ethnic differences in drug metabolism have been partly clarified because of the advances in molecular biology in recent years. Gene dosage determines the drug metabolism as demonstrated for S-mephenytoin and diazepam metabolism. Genotype analysis indicates a different frequency for the mutant alleles in different ethnic populations, which results in variations in the frequency of subjects who are homozygous for the mutant allele among the extensive metabolizers in different ethnic populations. Ethnic differences in drug metabolism may result from differences in distribution of a polymorphic trait and mutations which code for enzymes with abnormal activity which occur with altered frequency in different ethnic groups.
引用
收藏
页码:899 / 903
页数:5
相关论文
共 29 条
[1]   Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population [J].
Aynacioglu, AS ;
Sachse, C ;
Bozkurt, A ;
Kortunay, S ;
Nacak, M ;
Schröder, T ;
Kayaalp, SO ;
Roots, I ;
Brockmöller, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :185-192
[2]   WHY ARE DIAZEPAM METABOLISM AND POLYMORPHIC S-MEPHENYTOIN HYDROXYLATION ASSOCIATED WITH EACH OTHER IN WHITE AND KOREAN POPULATIONS BUT NOT IN CHINESE POPULATIONS [J].
BERTILSSON, L ;
KALOW, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (05) :608-610
[3]   INTERETHNIC DIFFERENCE IN OMEPRAZOLES INHIBITION OF DIAZEPAM METABOLISM [J].
CARACO, Y ;
TATEISHI, T ;
WOOD, AJJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :62-72
[4]  
Caraco Y, 1996, J PHARMACOL EXP THER, V278, P1165
[5]   Nomenclature for human CYP2D6 alleles [J].
Daly, AK ;
Brockmoller, J ;
Broly, F ;
Eichelbaum, M ;
Evans, WE ;
Gonzalez, FJ ;
Huang, JD ;
Idle, JR ;
IngelmanSundberg, M ;
Ishizaki, T ;
JacqzAigrain, E ;
Meyer, UA ;
Nebert, DW ;
Steen, VM ;
Wolf, CR ;
Zanger, UM .
PHARMACOGENETICS, 1996, 6 (03) :193-201
[6]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
[7]  
DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
[8]   GENETIC-ANALYSIS OF THE S-MEPHENYTOIN POLYMORPHISM IN A CHINESE POPULATION [J].
DEMORAIS, SMF ;
GOLDSTEIN, JA ;
XIE, HG ;
HUANG, SL ;
LU, YQ ;
XIA, H ;
XIAO, ZS ;
ILE, N ;
ZHOU, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) :404-411
[9]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187
[10]   POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].
EICHELBAUM, M ;
BERTILSSON, L ;
SAWE, J ;
ZEKORN, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186